|Bid||31.63 x 800|
|Ask||31.64 x 800|
|Day's Range||31.01 - 31.96|
|52 Week Range||31.01 - 43.90|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2022|
|Forward Dividend & Yield||1.04 (3.16%)|
|Ex-Dividend Date||Dec 01, 2022|
|1y Target Est||49.25|
Subscribe to Yahoo Finance Plus to view Fair Value for PRGO
Yahoo Finance health care reporter Anjalee Khemlani shares the latest on the ongoing baby formula shortage and how it may extend into spring 2023.
For well over a year now, we’ve been seeing headlines about inflation. The rate of price increases is running at its highest level since the early 1980s, although the October numbers, just released, showed it cooling off to 7.7% over the past 12 months. Covering the markets from investment giant JPMorgan, asset management investment chief David Kelly believes the trends are favorable looking forward. From June to October, the annualized inflation rate dropped from 9.1% to 7.7%, leading him to sa
Drug company Perrigo (NYSE: PRGO) experienced quite a headache on Tuesday after it released its third-quarter report before the bell. For the period, Perrigo booked total sales of $1.1 billion, which was nearly 6% higher on a year-over-year basis. Perrigo has a wide range of products in its portfolio.